Revolution Medicines, Inc.: Revision history

20 August 2022

• curprev 15:3515:35, 20 August 2022 95.149.241.133 talk 1,051 bytes +11 No edit summary undo

13 August 2022

• curprev 23:4123:41, 13 August 2022 109.180.50.163 talk 1,040 bytes +15 No edit summary undo

31 July 2022

• curprev 01:5901:59, 31 July 2022 >Chris 1,025 bytes +1,025 Created page with "Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperac..."